Hereditary Angioedema With C1 Esterase Inhibitor DeficiencyREAL-HAENCT07448181
Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema
An observational study of Hereditary Angioedema With C1 Esterase Inhibitor Deficiency and Hereditary Angioedema - Type 1, run by Istituti Clinici Scientifici Maugeri SpA at 1 site in Italy.
Trial summary
The aim of this study is to conduct an in-depth analysis of the Burden of Disease (BoD) perceived by patients with Hereditary Angioedema (HAE), through daily prospective observations based on Ecological Momentary Assessment (EMA) via digital surveys and standardised questionnaires. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
- What is being tested?
- ecological momentary assessment
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 23 Feb 2026to 28 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study involves the participation of adult patients with a confirmed diagnosis of hereditary angioedema, belonging to the ITACA (Italian Network for Hereditary and Acquired Angioedema) national cohort and receiving follow-up care at the IRCCS Maugeri Milano (Via Camaldoli) center. Participation in the study is voluntary and subject to the signing of informed consent. Patients will complete the questionnaires independently via their own smartphones, with no requirement for in-person visits.
Who may be able to join
- Confirmed diagnosis of Type 1 or Type 2 hereditary angioedema;
- Age ≥ 18 years;
- Ability to understand instructions and provide informed consent;
- Ownership and proficiency in using a personal smartphone compatible with the m-Path application (Android or iOS);
- Willingness to participate in the study for the entire duration of the observation period (8 weeks).
Who cannot join
- Diagnosis of acquired angioedema or other forms of angioedema unrelated to C1-inhibitor deficiency;
- Severe cognitive or psychiatric disorders that compromise the ability to complete the questionnaires independently;
- Age < 18 years;
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Istituti Clinici Scientifici Maugeri, Milan, Milan 20138
Milan, 20138
Francesca Perego, MD, PhD, 0250725239 ext. +39, francesca.perego@icsmaugeri.it
About this study
The aim of this study is to conduct an in-depth analysis of the Burden of Disease (BoD) perceived by patients with Hereditary Angioedema (HAE), through daily prospective observations based on Ecological Momentary Assessment (EMA) via digital surveys and standardised questionnaires.
Participants will answer online survey questions about their perceived burden of disease for 8 consecutive weeks. The main hypothesis is that daily prospective observation (EMA) will reveal a higher and more fluctuating burden of disease compared to traditional retrospective scales, providing a more accurate representation of the impact of HAE on patients' daily lives.
Read the detailed description
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent attacks of non-pruritic edema, localized at the subcutaneous, submucosal, and visceral levels. These attacks, caused by a temporary and localized increase in vascular permeability mediated by bradykinin, can affect the skin, gastrointestinal tract, face, genitals, and upper airways, resulting in a risk of asphyxiation. The most common forms of HAE are Type 1 (85-90%), caused by a quantitative deficiency of C1-inhibitor (HAE-C1INH-Type1), and Type 2 (10-15%), due to a qualitative dysfunction of the same (HAE-C1INH-Type2). In Italy, the overall prevalence is estimated at approximately 1:65,000.
HAE attacks occur unpredictably, with an average frequency that is highly heterogeneous between subjects, ranging on average from 1 to 26 episodes per year; some severe cases can reach 100 attacks per year. These manifestations have an average duration of about 2-5 days and are often debilitating, significantly compromising quality of life (QoL) and the subject's functional abilities. The impact of the disease is not limited to the presence, duration, or frequency of attacks but persists during intercritical periods, often accompanied by anticipatory anxiety and a constant sense of vulnerability, which can lead to a state of hypervigilance.
Numerous studies describe the Burden of Disease (BoD) as multidimensional. The impact on QoL concerns physical, psychological, social, and professional dimensions. From a psychological and emotional perspective, many HAE patients report high levels of stress, anxiety, and depressive symptoms, often linked to the unpredictability of attacks and the perception of poor control over their condition. Furthermore, despite therapeutic progress, the potential risk of fatal laryngeal edema remains a significant source of concern for many patients, contributing to a persistent emotional burden.
At the professional level, a reduction in productivity is observed due to both absenteeism and presenteeism, with European studies documenting an average of up to 20 days lost per year between school and work. Finally, on a social level, some patients report experiences of stigmatization or discrimination, with a negative impact on relational well-being and social integration.
Until now, BoD in HAE has been assessed primarily through retrospective questionnaires and standardized measures administered at single time points, such as the Angioedema Quality of Life (AE-QoL), the Angioedema Activity Score (AAS), or the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH). While validated and widely used, these instruments present several methodological limitations. In particular, they rely on subjective estimates reported within more or less broad time windows (e.g., the last two weeks or the previous month) and are therefore susceptible to recall bias, the mnemonic distortion in the reconstruction of past experiences. Moreover, these tools are developed to provide a static snapshot of subjective BoD, which may fail to capture the dynamic trends and the intra- and inter-individual fluctuations typical of the HAE experience, especially concerning emotional, social, or symptomatic events occurring in daily life.
In light of these considerations, this study will apply the Ecological Momentary Assessment (EMA) method. This is an innovative observational data collection method that allows for the repeated collection of self-report data over time through brief questionnaires sent to the participant's smartphone at specific and/or random moments of the day. EMAs are based on simple, intuitive, and quick items, similar to those found in traditional psychometric tools, but administered multiple times over time and within the context of the patient's real life.
This approach offers a twofold advantage:
- It reduces recall bias, as the person is prompted to respond in real-time or in close temporal proximity to the experience.
- It allows for the collection of data with high ecological validity, meaning data that is relevant to the subject's behavior and experience in their natural environment.
This allows for a more precise exploration of the characteristics that constitute BoD in HAE and, consequently, the daily impact of the disease. The present protocol aims to analyze in depth the Burden of Disease (BoD) perceived by HAE patients through daily and prospective observation based on EMAs and standardized scales.
- Conditions
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
- Being tested
- ecological momentary assessment
- Keywords
- Hereditary Angioedema, Burden of disease, Ecological Momentary Assessment, Quality of Life
- Medical subject headings
- Angioedemas, Hereditary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ecological momentary assessmentOther
A real-time data collection method involving brief, repeated digital surveys completed by participants in their natural environments. Participants will receive two notifications every other day for 8 weeks via a mobile application. Surveys are designed to assess physical symptoms, socio-occupational status, and emotional states related to Hereditary Angioedema (HAE) to capture daily fluctuations in disease burden.
What is being measured
The primary outcome is the main question the study is designed to answer.
Emotional Burden via Ecological Momentary Assessment (EMA)
Evaluation of emotional states (anxiety, mood, stress, and fear of attacks) through a Visual Analogue Scale (VAS). Each item is scored on a range from 0 to 100, where 0 indicates "no emotional impact" and 100 indicates "maximum emotional distress.
Measured: Every other day for 8 weeks
Socio-occupational Impairment via Ecological Momentary Assessment (EMA)
Assessment of the impact of Hereditary Angioedema (HAE) on daily, social, and professional activities. Measured via a scale ranging from 1 to 10, where 1 indicates "no impairment" and 10 indicates "maximum perceived impairment"
Measured: Every other day for 8 weeks
Disease Activity
Assessment of the physical burden using the Angioedema Activity Score (AAS): A daily symptom diary, total score from 0 to 15.
Measured: AAS is collected every other day for 8 weeks
Angioedema Quality of Life
Assessment of quality of life impairment using the AE-QoL questionnaire. The total score ranges from 17 to 85, where higher scores indicate greater impairment.
Measured: After 4 weeks and at the end of the 8 weeks
Disease Control
Assessment of disease control using the AECT. The total score ranges from 0 to 16, where lower scores indicate poorer disease control.
Measured: After 4 weeks and at the end of the 8 weeks.
Secondary outcomes (5)
Anxiety and Depressive Symptoms
Measured via the Patient Health Questionnaire-4 (PHQ-4), a 4-item screening scale for anxiety and depression. Each item is scored from 0 to 3. The total score ranges from 0 to 12, where higher scores indicate more severe symptoms of anxiety and depression.
Measured: Every other week for 8 weeks
Work Productivity and Activity Impairment (WPAI:GH)
The WPAI:GH measures the impact of health problems on work productivity and daily activities. It yields four scores: absenteeism, presenteeism, overall work impairment, and activity impairment. Results are expressed as percentages (0-100%), where higher percentages indicate greater impairment.
Measured: Once a week for 8 weeks
Within-person Variability of Emotional States (EMA)
Calculated as the standard deviation or Mean Successive Difference (MSSD) of the daily emotional VAS scores (0-100) collected via EMA over the 8-week period. This measures the "fluctuations" of the patient's emotional state.
Measured: Every other day for 8 weeks
Difference in Burden of Disease between LTP and ODT groups
Comparison of the mean Burden of Disease (BoD) scores across all dimensions (physical, emotional, socio-occupational) between patients receiving Long-Term Prophylaxis (LTP) and those receiving On-Demand Treatment (ODT).
Measured: 8 weeks
Correlation between EMA scores and Traditional Questionnaires
Comparison between the real-time daily scores (EMA) and the retrospective scores (AE-QoL, WPAI:GH, PHQ-4) to measure the difference in patient perception of disease burden.
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2026
- Study start23 Feb 2026
- Primary completion28 Feb 2027 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hereditary Angioedema With C1 Esterase Inhibitor DeficiencyStudies of the same condition, open and under way.
- More trials run by Istituti Clinici Scientifici Maugeri SpAThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07448181
- Sponsor's protocol ID
- 2025-3.11/388
- Acronym
- REAL-HAE
- Status last verified
- Mar 2026
- First submitted
- 26 Feb 2026
- Last updated
- 4 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema
- ClinicalTrials.gov ID
- NCT07448181
- Acronym / sponsor ID
- REAL-HAE / 2025-3.11/388
- Conditions
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
- Keywords
- Hereditary Angioedema, Burden of disease, Ecological Momentary Assessment, Quality of Life
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpAUniversity, hospital or other
- Study start
- 23 Feb 2026 (actual)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 4 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to conduct an in-depth analysis of the Burden of Disease (BoD) perceived by patients with Hereditary Angioedema (HAE), through daily prospective observations based on Ecological Momentary Assessment (EMA) via digital surveys and standardised questionnaires.
Participants will answer online survey questions about their perceived burden of disease for 8 consecutive weeks. The main hypothesis is that daily prospective observation (EMA) will reveal a higher and more fluctuating burden of disease compared to traditional retrospective scales, providing a more accurate representation of the impact of HAE on patients' daily lives.
Detailed description
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent attacks of non-pruritic edema, localized at the subcutaneous, submucosal, and visceral levels. These attacks, caused by a temporary and localized increase in vascular permeability mediated by bradykinin, can affect the skin, gastrointestinal tract, face, genitals, and upper airways, resulting in a risk of asphyxiation. The most common forms of HAE are Type 1 (85-90%), caused by a quantitative deficiency of C1-inhibitor (HAE-C1INH-Type1), and Type 2 (10-15%), due to a qualitative dysfunction of the same (HAE-C1INH-Type2). In Italy, the overall prevalence is estimated at approximately 1:65,000.
HAE attacks occur unpredictably, with an average frequency that is highly heterogeneous between subjects, ranging on average from 1 to 26 episodes per year; some severe cases can reach 100 attacks per year. These manifestations have an average duration of about 2-5 days and are often debilitating, significantly compromising quality of life (QoL) and the subject's functional abilities. The impact of the disease is not limited to the presence, duration, or frequency of attacks but persists during intercritical periods, often accompanied by anticipatory anxiety and a constant sense of vulnerability, which can lead to a state of hypervigilance.
Numerous studies describe the Burden of Disease (BoD) as multidimensional. The impact on QoL concerns physical, psychological, social, and professional dimensions. From a psychological and emotional perspective, many HAE patients report high levels of stress, anxiety, and depressive symptoms, often linked to the unpredictability of attacks and the perception of poor control over their condition. Furthermore, despite therapeutic progress, the potential risk of fatal laryngeal edema remains a significant source of concern for many patients, contributing to a persistent emotional burden.
At the professional level, a reduction in productivity is observed due to both absenteeism and presenteeism, with European studies documenting an average of up to 20 days lost per year between school and work. Finally, on a social level, some patients report experiences of stigmatization or discrimination, with a negative impact on relational well-being and social integration.
Until now, BoD in HAE has been assessed primarily through retrospective questionnaires and standardized measures administered at single time points, such as the Angioedema Quality of Life (AE-QoL), the Angioedema Activity Score (AAS), or the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH). While validated and widely used, these instruments present several methodological limitations. In particular, they rely on subjective estimates reported within more or less broad time windows (e.g., the last two weeks or the previous month) and are therefore susceptible to recall bias, the mnemonic distortion in the reconstruction of past experiences. Moreover, these tools are developed to provide a static snapshot of subjective BoD, which may fail to capture the dynamic trends and the intra- and inter-individual fluctuations typical of the HAE experience, especially concerning emotional, social, or symptomatic events occurring in daily life.
In light of these considerations, this study will apply the Ecological Momentary Assessment (EMA) method. This is an innovative observational data collection method that allows for the repeated collection of self-report data over time through brief questionnaires sent to the participant's smartphone at specific and/or random moments of the day. EMAs are based on simple, intuitive, and quick items, similar to those found in traditional psychometric tools, but administered multiple times over time and within the context of the patient's real life.
This approach offers a twofold advantage:
- It reduces recall bias, as the person is prompted to respond in real-time or in close temporal proximity to the experience.
- It allows for the collection of data with high ecological validity, meaning data that is relevant to the subject's behavior and experience in their natural environment.
This allows for a more precise exploration of the characteristics that constitute BoD in HAE and, consequently, the daily impact of the disease. The present protocol aims to analyze in depth the Burden of Disease (BoD) perceived by HAE patients through daily and prospective observation based on EMAs and standardized scales.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study involves the participation of adult patients with a confirmed diagnosis of hereditary angioedema, belonging to the ITACA (Italian Network for Hereditary and Acquired Angioedema) national cohort and receiving follow-up care at the IRCCS Maugeri Milano (Via Camaldoli) center. Participation in the study is voluntary and subject to the signing of informed consent. Patients will complete the questionnaires independently via their own smartphones, with no requirement for in-person visits.
Key inclusion criteria (5 listed)
- Confirmed diagnosis of Type 1 or Type 2 hereditary angioedema;
- Age ≥ 18 years;
- Ability to understand instructions and provide informed consent;
- Ownership and proficiency in using a personal smartphone compatible with the m-Path application (Android or iOS);
- Willingness to participate in the study for the entire duration of the observation period (8 weeks).
Key exclusion criteria (3 listed)
- Diagnosis of acquired angioedema or other forms of angioedema unrelated to C1-inhibitor deficiency;
- Severe cognitive or psychiatric disorders that compromise the ability to complete the questionnaires independently;
- Age < 18 years;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ecological momentary assessmentA real-time data collection method involving brief, repeated digital surveys completed by participants in their natural environments. Participants will receive two notifications every other day for 8 weeks via a mobile application. Surveys are designed to assess physical symptoms, socio-occupational status, and emotional states related to Hereditary Angioedema (HAE) to capture daily fluctuations in disease burden. | Other | – |
Primary outcome
Emotional Burden via Ecological Momentary Assessment (EMA)
Time frame: Every other day for 8 weeks
Evaluation of emotional states (anxiety, mood, stress, and fear of attacks) through a Visual Analogue Scale (VAS). Each item is scored on a range from 0 to 100, where 0 indicates "no emotional impact" and 100 indicates "maximum emotional distress.
Socio-occupational Impairment via Ecological Momentary Assessment (EMA)
Time frame: Every other day for 8 weeks
Assessment of the impact of Hereditary Angioedema (HAE) on daily, social, and professional activities. Measured via a scale ranging from 1 to 10, where 1 indicates "no impairment" and 10 indicates "maximum perceived impairment"
Disease Activity
Time frame: AAS is collected every other day for 8 weeks
Assessment of the physical burden using the Angioedema Activity Score (AAS): A daily symptom diary, total score from 0 to 15.
Angioedema Quality of Life
Time frame: After 4 weeks and at the end of the 8 weeks
Assessment of quality of life impairment using the AE-QoL questionnaire. The total score ranges from 17 to 85, where higher scores indicate greater impairment.
Disease Control
Time frame: After 4 weeks and at the end of the 8 weeks.
Assessment of disease control using the AECT. The total score ranges from 0 to 16, where lower scores indicate poorer disease control.
5 secondary outcomes
Anxiety and Depressive Symptoms
Time frame: Every other week for 8 weeks
Work Productivity and Activity Impairment (WPAI:GH)
Time frame: Once a week for 8 weeks
Within-person Variability of Emotional States (EMA)
Time frame: Every other day for 8 weeks
Difference in Burden of Disease between LTP and ODT groups
Time frame: 8 weeks
Correlation between EMA scores and Traditional Questionnaires
Time frame: 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
RecruitingPhase 3
Donidalorsen Treatment in Children With Hereditary Angioedema
Hereditary Angioedema (HAE)
RecruitingObservational study
A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
Hereditary Angioedema (HAE)
Active, not recruitingPhase 3
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Hereditary Angioedema
RecruitingPhase 3
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Acute Hereditary Angio Edema
Active, not recruitingPhase 1/2
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
Hereditary Angioedema
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Istituti Clinici Scientifici Maugeri, Milan, Milan 20138
Milan, Italy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hereditary Angioedema With C1 Esterase Inhibitor Deficiency and Hereditary Angioedema - Type 1, run by Istituti Clinici Scientifici Maugeri SpA at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Emotional Burden via Ecological Momentary Assessment (EMA) (time frame: Every other day for 8 weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.